A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets

MindWalk Holdings Corp. Announces Leadership Update

AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.

MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test

MindWalk Holdings Corp. Strengthens Boston-Based Development Leadership as Pipeline Advances Toward Preclinical Efficacy Studies

Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context

MindWalk (NASDAQ: HYFT): Enterprise AI Has Found Its Ontology Layer. Biology Needs One Grounded in Biological Function

AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment

MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director